Jade Biosciences
JBIO· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +59.2% in FY2025
Tom Frohlich is the CEO of Jade Biosciences and was paid $9.8M in FY2025 (Dec), up 618%.
Pay$100 in the stock at the end of FY23 → $19
Executives4
See all- 1Tom FrohlichChief Executive Officer, President and DirectorFY2025
- 2Andrew King, Ph.D.President, Research and DevelopmentFY2025
- 3Bradford DahmsChief Financial OfficerFY2025
- 4Timothy NoyesFormer Chief Executive OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allJade Biosciences paid its 4 named executives $20.3M in total in FY2025 (Dec). CEO Tom Frohlich was paid $9.8M of that.
| Name | |||
|---|---|---|---|
| Tom FrohlichChief Executive Officer, President and Director | Not disclosed | ||
| Andrew King, Ph.D.President, Research and Development | Not disclosed | ||
| Bradford DahmsChief Financial Officer | Not disclosed | Not disclosed | |
| Timothy NoyesFormer Chief Executive Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers20
See allThe comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board5
See all- Eric Dobmeier, J.D.Chair · 0 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive
- Erin LavelleDirector · 0 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Lawrence Klein, Ph.D.Director · 0 yr on the boardIndependentAudit, Nominating and Corporate Governance (Chair)—Paid as an executive
- Tom FrohlichDirector · 0 yr on the boardNot independent—Paid as an executive
- Tomas KiselakDirector · 0 yr on the boardIndependentCompensation (Chair)—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings5
See all| Proxy statement | DEF 14A | Apr 28, 2026 | FY2025 |
| Annual report | 10-K | Mar 6, 2026 | FY2025 |
| Annual report | 10-K | Mar 27, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 25, 2024 | FY2023 |
